Nilemdo

Indicated For

primary hypercholesterolaemia, mixed dyslipidaemia, atherosclerotic cardiovascular disease

About This Medication

# Nilemdo Patient Guide: How to Get Nilemdo at Low or No Cost Nilemdo (bempedoic acid) is a prescription medication used to help lower cholesterol and reduce the risk of heart attacks in adults who cannot take statins or need additional treatment.[1][2][4] This guide explains the **NEXSTEP Patient Support Program**, the primary assistance option from the manufacturer, which offers a Co-Pay Card for eligible patients to pay as little as **$10 for a 30-day supply** or **$25 for a 90-day supply** if you have commercial insurance.[1][2][5] ## About Nilemdo (Bempedoic Acid) Nilemdo, also known as the active ingredient bempedoic acid in brands like **Nexletol** and **Nexlizet**, works by blocking an enzyme in the liver that produces cholesterol.[1][2][4] It is indicated for adults with: - Established cardiovascular disease (CVD), or - High risk for CVD events, who are unable to take recommended statin therapy (including those not currently on a statin).[2][4] This helps reduce **LDL cholesterol (bad cholesterol)** and lowers the risk of myocardial infarction (heart attack) and coronary revascularization procedures like stents or bypass surgery.[1][2] **Who it's for:** Patients with high cholesterol who experience statin side effects (e.g., muscle pain), cannot tolerate statins, or need extra lowering beyond statins alone. Always consult your doctor to see if Nilemdo is right for you.[1][4] ## Who Qualifies for Assistance? The **NEXSTEP Patient Support Program** primarily targets patients with **commercial insurance** (private plans, not government programs like Medicare or Medicaid).[1][2][5] Key eligibility: - Valid prescription for Nilemdo (or equivalent bempedoic acid products like Nexletol/Nexlizet). - Coverage under a commercial prescription drug plan. - No restrictions noted on income for the Co-Pay Card, making it accessible to many insured patients.[2][5] For **Medicare patients**, coverage is broad: over 90% of Medicare payers approve prescriptions, with 8 out of 10 scripts approved and average copays around **$43** for a 30-day supply (as of Q3 2024).[2] Medicare Part D may cover it, but prior authorization (PA) could be needed.[2][7][8] **Uninsured or low-income patients:** No direct manufacturer patient assistance program (PAP) for free medication is detailed in available resources. Instead, explore third-party options like **Simplefill** (helps apply to PAPs), **PAN Foundation** (up to $3,800/year for hypercholesterolemia copays), or **Medicare Extra Help** (for low-income seniors).[3][6][7] ## Income Eligibility Breakdown NEXSTEP Co-Pay Card has **no specific income thresholds**—it's mainly insurance-based.[2][5] For broader low-income aid like Medicare Extra Help or PAN Foundation, eligibility ties to **Federal Poverty Level (FPL)**. Here's a general table (2026 estimates; check official sites for updates): | Household Size | Annual Income Limit (100% FPL) | Medicare Extra Help (135-150% FPL approx.) | PAN Foundation Notes | |----------------|-------------------------------|--------------------------------------------|---------------------| | Individual | ~$15,060 | Up to ~$20,300 | Copay grants up to $3,800/year[6] | | Couple | ~$20,440 | Up to ~$27,600 | Diagnosis-based[6] | | Family of 3 | ~$25,820 | Up to ~$34,900 | Income proof required | | Family of 4 | ~$31,200 | Up to ~$42,100 | Assets also considered for Extra Help[7] | *Notes: FPL varies by year/location. Co-Pay Card ignores income.[1][2] Always verify with program.[7]* ## Insurance Requirements - **Commercial Insurance:** Eligible for Co-Pay Card ($10/30-day or $25/90-day).[1][2][5] Activate at NexCopay.com or via NEXSTEP.[4][5] - **Medicare:** Widely covered (90%+ payers); average copay $43/30-day. PA may require diagnosis, statin history, LDL-C levels.[2][7][8] - **Medicaid/Uninsured:** Not directly covered by NEXSTEP Co-Pay; use PAPs like Simplefill or PAN.[3][6] Some plans need **prior authorization (PA)**—your doctor submits diagnosis and lab details.[2] ## Step-by-Step Application Process 1. **Get Prescribed:** Ask your doctor for Nilemdo if you have high cholesterol and can't use statins.[1] 2. **Check Insurance:** Confirm coverage with your plan. For Medicare, call provider.[7][8] 3. **Enroll in NEXSTEP:** Visit nexlizet.com/patient-support or nexletol.com. Call representatives for Co-Pay Card help.[1][4] 4. **Activate Co-Pay Card:** Go to activatethecard.com/7883/welcome or NexCopay.com. Provide insurance details.[5] 5. **For Low-Income Aid:** Apply to Simplefill (online/phone 1-877-386-0206) or PAN Foundation.[3][6] 6. **Fill Prescription:** Use at pharmacy. Opt for 90-day mail-order to save time/money.[8] NEXSTEP offers education on cholesterol and activation support.[1][4] ## Timeline and Delivery - **Co-Pay Card Approval:** Instant upon activation if eligible.[5] - **Medicare PA:** Varies by plan; often quick if docs provided.[2] - **Third-Party PAPs:** Simplefill processes in days; monitors refills.[3] PAN grants processed per application. - **Delivery:** Standard pharmacy pickup or mail-order (90-day supplies possible).[8] No specific processing time for NEXSTEP beyond card activation. ## Alternatives if Denied or Ineligible - **Switch Pharmacies/Use GoodRx:** Compare prices; mail-order for discounts.[8] - **90-Day Supplies:** Reduces copays/trips.[8] - **Other PAPs:** NeedyMeds, Medicine Assistance Tool, or hypercholesterolemia funds.[6][8] - **Generics/Biosimilars:** None available for bempedoic acid (brand-only).[7] - **Extra Help for Medicare:** Apply if low-income.[7] - **Doctor Discussion:** Explore statins or other cholesterol meds. ## Disclaimer This guide is for informational purposes only and based on available data as of 2026. Eligibility, coverage, and copays can change—always verify with your doctor, pharmacist, insurer, or program (e.g., NEXSTEP at nexlizet.com).[1][2] Not medical/financial advice. Contact programs directly for personalized help. Word count: 1028.

Program information last verified: March 30, 2026